People compare ATX-304 and SANA/MVD1 as if they are two versions of the same fat burner.
They are not.
The comparison is interesting because both are being studied in the metabolic-disease and weight-loss space, but they approach the problem through different biological jobs. Their evidence is also early: small human studies and conference data sit alongside a much larger amount of mechanistic and animal work.
SANA is the more targeted thermogenic idea
SANA—called MVD1 in clinical development—is a nitroalkene derivative of salicylate. The central finding in the published work is increased creatine-dependent energy expenditure in adipose tissue.
In preclinical models, the effect was independent of appetite reduction, UCP1, and AMPK activation. The weight-loss effect was lost when creatine-dependent thermogenesis was disrupted. The same paper included a short randomized Phase 1A/B trial focused primarily on safety and tolerability, with exploratory weight and glucose findings over 15 days. Read the 2025 Nature Metabolism paper.
The simplest conceptual version is:
Stored energy → heat.
That makes SANA interesting as an appetite-independent expenditure mechanism. “Creatine-dependent” does not mean taking supplemental creatine has been shown to amplify SANA. It has not.
ATX-304 is broader
ATX-304, formerly O304, is described as a dual AMPK and mitochondrial activator. AMPK is a cellular energy-sensing network that can shift metabolism away from energy-consuming synthesis and toward processes including glucose uptake and fatty-acid oxidation.
In mouse models of metabolic liver disease, ATX-304 reduced body fat, cholesterol, liver steatosis, and fibrosis while shifting the liver toward greater fatty-acid oxidation and less fatty-acid synthesis. Read the peer-reviewed JCI Insight paper.
The first small Phase 1b human report enrolled 23 adults with obesity and prediabetes. Participants were randomized 2:1 to 400 mg oral ATX-304 or placebo for eight weeks, with an optional extension. The conference abstract reported favorable changes from baseline in adiponectin, liver fat, visceral fat, and resting metabolic rate, with larger Phase 2 studies planned. Those results are promising, but they remain a small early-stage study reported as an abstract rather than a full peer-reviewed outcomes paper. Read the 2026 ADA abstract.
A companion mechanistic abstract reported that ATX-304’s AMPK activation was not secondary to a decline in cellular ATP. Read the mechanism abstract.
The simplest conceptual version is:
Change how multiple tissues acquire, process, and expend fuel.
For a narrow question about adipose-focused thermogenesis, SANA is the cleaner mechanism. For a broader question involving glucose handling, liver fat, visceral fat, lipids, and metabolic flexibility, ATX-304 is the more comprehensive mechanism.
The rest of the stack changes the question
Mechanisms never enter an empty body or an empty routine. The marginal value of an intervention depends on what is already doing the same—or an adjacent—job.
Incretin-based weight loss
GLP-1 and multi-agonist therapies already create a strong fat-loss environment, primarily by changing appetite and energy intake, with some agents adding glucagon-receptor activity.
SANA may represent an appetite-independent expenditure pathway. ATX-304 may offer broader metabolic effects. But the marginal value of either may be smaller when weight is already falling rapidly. More expenditure is not automatically a better result if it appears as poorer recovery, lower training output, or a deficit larger than intended.
The SANA paper explicitly frames complementary approaches to incretin therapy as a potential use case. ATX-304’s developers are also studying it as an orthogonal mechanism. Neither framing establishes the outcome or safety of personally combining them with other agents.
A crowded metabolic neighborhood
SLU-PP compounds, MOTS-c, metformin, berberine, and large amounts of cardio are not interchangeable. But they can converge around AMPK signaling, mitochondrial activity, glucose disposal, oxidative metabolism, or exercise-like energy signaling.
More pathway activation does not automatically mean proportionally more fat loss. It can also create diminishing returns, lower energy availability, and an attribution problem: if several interventions move together, I lose the ability to identify which one produced the result.
SANA is more orthogonal to that group because its proposed mechanism centers on adipose creatine thermogenesis rather than AMPK.
Growth-hormone context
Growth-hormone signaling can increase lipolysis while making glucose and insulin management more difficult. That makes ATX-304’s glucose and insulin-sensitivity research conceptually complementary to a GH-heavy body-composition context.
SANA could add expenditure, but its central mechanism does not directly answer the glucose-management side of that equation. This is a mechanistic comparison, not evidence that either combination is safe or effective.
Other thermogenic pressure
Rauwolscine, yohimbine, clenbuterol, beta-3 agonists, and other thermogenic interventions may act differently from SANA. They can still converge on the same physiological outcome:
- More heat production
- More sweating
- Higher energy requirements
- Potentially worse sleep or recovery
- A deficit larger than intended
That matters even when each individual input feels mild.
Muscle preservation changes how I weight them
SANA is theoretically the cleaner fit for a question focused on direct fat loss while preserving lifting performance because its proposed action is comparatively adipose-centered.
ATX-304 activates AMPK across peripheral tissues, including skeletal muscle. AMPK supports glucose uptake, fat oxidation, and mitochondrial adaptation, but sustained AMPK signaling can sit in tension with mTORC1 signaling involved in muscle-protein synthesis.
That does not mean ATX-304 erases gains. The small human abstract reported no such conclusion. It means broad AMPK activation is not automatically a free addition for someone lifting frequently and prioritizing hypertrophy. SANA could still undermine performance indirectly if expenditure pushed the deficit too far.
When I first wrote this comparison, my conceptual weighting looked like this:
- For direct fat loss while protecting lifting performance: SANA 65%, ATX-304 35%.
- For visceral fat, fatty liver, insulin sensitivity, and broader metabolic cleanup: ATX-304 70%, SANA 30%.
Those percentages are not calculated efficacy estimates, probabilities, or suggested allocations. They describe how strongly each mechanism fits the question in my own decision framework.
Separate the experiments
For an already complicated fat-loss stack, the first move should not be adding SANA and ATX-304 together. The first move is deciding which question is being asked.
The SANA question is:
Does an adipose-focused thermogenic mechanism produce an additional visible fat-loss signal without degrading training and recovery?
The ATX-304 question is:
Does a broader AMPK and mitochondrial intervention improve metabolic markers and body composition while strength remains stable?
Those are separate experiments.
The most sophisticated stack is not the one with the most pathways activated. It is the one where every intervention has a distinct job—and the record can still show whether it did that job.